Navigation Links
Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
Date:1/9/2014

CAMBRIDGE, Mass., Jan. 9, 2014 /PRNewswire/ -- Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced the appointment of Alicia Secor to the newly created position of Chief Commercial Officer, and the appointment of  John L. LaMattina to the Company's Board of Directors.

Ms. Secor joins Zafgen as an experienced health care executive with over 15 years of global leadership and commercial operating experience with an established track record in leading the commercial development, product management, and global expansion of products across various therapeutic areas including metabolic diseases.  She most recently served as Senior Vice President and Chief Operating Officer of Synageva BioPharma Corp. 

Dr. LaMattina brings significant experience in business, partnership and product development spanning his 30-year career at Pfizer.

"We are thrilled to welcome Alicia to our executive team and John to our Board of Directors at such a pivotal time in Zafgen's development," said Thomas Hughes, Ph.D., President and Chief Executive Officer of Zafgen.  "We are approaching a number of key milestones in our development of beloranib, including the expected results of our Phase 2a trial in patients with Prader-Willi syndrome, and I am confident that the addition of Alicia's strategic leadership and commercial knowledge and proficiency, as well as John's broad drug discovery and development expertise, will prove invaluable as we continue to pursue our goal of bringing beloranib to market for severely obese patients."

Previously, Ms. Secor spent fifteen years at Genzyme, a Sanofi Company, where she held various leadership positions, most recently as Vice President and General Manager of Metabolic Diseases, a global business consisting of five marketed products, incl
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Zafgen Secures $45 Million in Series E Financing
2. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
3. Zafgen Secures $21 Million in Series D Financing
4. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
5. Mylan Appoints Adele Gulfo as EVP, Global Collaboration and Strategic Operations
6. Lakewood-Amedex Inc. Appoints Geoffrey F. Cox To Its Board Of Directors
7. Kite Pharma Appoints Cynthia M. Butitta as Chief Financial Officer
8. Auspex Raises $35 Million And Appoints Industry Veteran Gerald Proehl To Its Board of Directors
9. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
10. KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
11. MIMETAS Appoints BHI Entrepreneur-in-Residence Todd Chappell as General Manager, U.S. Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... led by researchers at UC Davis has shown that ... role in cell division, also boosts the mitochondrial activity ... the complex has been shown to perform both jobs. ... target to control cellular energy production, potentially advancing cancer ... today in the journal Developmental Cell . , ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... shocking rates of suicide are highest in areas with ... smallholdings less than one hectare and trying ... that are highly susceptible to global price fluctuations. , ... that point to a crisis in key areas of ... economy during the 90s. Researchers say that policy intervention ...
Breaking Medicine News(10 mins):Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3
... the world's leading manufacturer and distributor of automated ... have its newest health station, the LC600 at ... be held at the Venetian Resort, Las Vegas, ... will be located in the Pharmacy of the ...
... July 3 The following is the,National Council ... The Bulletin, which is free of charge and ... you the latest issues and news affecting people ... to, http://listserv.access.gpo.gov, click on Online mailing list ...
... successfully introduced by P.-I. Brnemark and co-workers in ... years of research and development, titanium is currently ... titanium-based materials are often used to replace lost ... are some alternatives to modulating the body,s response ...
... Group, Inc. (MED3OOO), a,national leader in healthcare management ... has entered into a partnership,arrangement with Mitsui & ... & Co., Ltd. (Mitsui). The agreement with Mitsui ... of being a global "premier,strategic operations partner" for ...
... SAN FRANCISCO, Calif., July 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... Executive Officer and President, will provide a corporate,overview at ... p.m. Eastern Time on July 8, 2008 in New ... of the presentation by visiting,the Sunesis website at ...
... Therapeutics Inc.,("Transition" or the "Company") (TSX: TTH; NASDAQ: ... is pleased to announce that Mr. Elie,Farah has ... serve as,Chief Financial Officer, and Ms. Nicole Rusaw-George ... "These promotions reflect the strength of our ...
Cached Medicine News:Health News:Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future 2Health News:Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future 3Health News:Lifeclinic to Feature Latest Health Stations at McKesson's Pharmacy of the Future 4Health News:National Council on Disability Monthly Bulletin for June, 2008 2Health News:National Council on Disability Monthly Bulletin for June, 2008 3Health News:National Council on Disability Monthly Bulletin for June, 2008 4Health News:National Council on Disability Monthly Bulletin for June, 2008 5Health News:MED3OOO and Mitsui & Co. Complete U.S. and Global Healthcare Partnership Agreement 2Health News:MED3OOO and Mitsui & Co. Complete U.S. and Global Healthcare Partnership Agreement 3Health News:Transition Therapeutics Announces Executive Management Appointments 2
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
This unique kit contains three pipettes conveniently packaged with useful accessoriesat an economical price....
... immunochromatography based one step in vitro test. ... and its metabolite in human urine,specimens. The ... a cut-off level of 300 ng/mL,can be ... in the point of care location and ...
... unique kit contains three pipettes ... an economical price. Three classic ... Two racks of certified-quality Diamond ... adhesive-backed Single Pipette Hangers 10 ...
Medicine Products: